The European Commission has cleared the planned acquisition of generic pharmaceutical company Actavis by Deutsche Bank.
Headquartered in Iceland, Actavis has a major plant in Malta and recently announced a €12m investment in a new warehouse and research facility.
The European Commission concluded that the take-over would not significantly impede effective competition in the European Economic Area (EEA) or any substantial part of it.
Deutsche Bank is Actavis's most important creditor and is to acquire control over the company due to rights reserved to Deutsche Bank following a financial restructuring.